Related Experiment Videos

[Clinical probes using tumor necrosis factor in treatment of neoplastic diseases]

A Szczepanik1, J Tabor, M Siedlar

  • 1Zakładu Immunologii Klinicznej, i Mikrobiologii Polsko-Amerykańskiego, Instytutu Pediatrii Akademii Medycznej, Krakowie.

Przeglad Lekarski
|January 1, 1994
PubMed

Insights

Tumor necrosis factor (TNF), a cytokine from macrophages, exhibits anti-cancer properties in lab and animal studies. Clinical trials are evaluating its safety and effectiveness for cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cytokine Biology

Context:

  • Tumor necrosis factor (TNF) is a key cytokine produced by activated macrophages.
  • Preclinical studies demonstrate TNF's antineoplastic activity in vitro and in vivo tumor models.
  • TNF is being investigated for its potential in cancer treatment.

Purpose:

  • To survey and assess the results of clinical trials involving TNF administration.
  • To evaluate the toxic effects, pharmacokinetics, and therapeutic efficacy of TNF.
  • To determine the role of TNF in oncological immunotherapy.

Summary:

  • This paper reviews clinical trial data (Phase I and II) on Tumor Necrosis Factor (TNF).
  • The review focuses on assessing TNF's toxic effects, pharmacokinetics, and therapeutic outcomes.
  • Findings aim to inform the evaluation of TNF's contribution to cancer immunotherapy.

Impact:

  • Provides a comprehensive overview of clinical findings for TNF in cancer treatment.
  • Informs future research and clinical applications of TNF for oncological immunotherapy.
  • Contributes to understanding the therapeutic potential of cytokines in cancer care.

Related Concept Videos